Doxorubicin is a standard chemotherapy drug used to treat many types of cancer, including endometrial cancer. However, in some patients the cancer continues to grow. Doctors are therefore seeking more effective drugs for this cancer.
AEZS-108 is an investigational drug composed of doxorubicin plus a kind of hormone that helps doxorubicin stick to and enter docking sites for this hormone (called LHRH receptors). In this study, researchers are comparing the effectiveness of AEZS-108 with doxorubicin in women with endometrial cancer that has returned or spread after initial therapy. Patients will receive AEZS-108 or doxorubicin. Each drug is given intravenously (by vein).